Kainos Medicine Inc - Asset Resilience Ratio

Latest as of March 2025: 48.13%

Kainos Medicine Inc (284620) has an Asset Resilience Ratio of 48.13% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 284620 current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

₩6.43 Billion

≈ $4.36 Million USD Cash + Short-term Investments

Total Assets

₩13.36 Billion

≈ $9.06 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how Kainos Medicine Inc's Asset Resilience Ratio has changed over time. See 284620 net asset value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Kainos Medicine Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Kainos Medicine Inc.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩6.43 Billion	48.13%
Short-term Investments	₩0.00	0%
Total Liquid Assets	₩6.43 Billion	48.13%

Asset Resilience Insights

Very High Liquidity: Kainos Medicine Inc maintains exceptional liquid asset reserves at 48.13% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Kainos Medicine Inc Industry Peers by Asset Resilience Ratio

Compare Kainos Medicine Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.10%
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	4.52%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	35.56%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Kainos Medicine Inc (2017–2024)

The table below shows the annual Asset Resilience Ratio data for Kainos Medicine Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	35.69%	₩3.83 Billion ≈ $2.60 Million	₩10.74 Billion ≈ $7.28 Million	-42.16pp
2023-12-31	77.85%	₩16.34 Billion ≈ $11.07 Million	₩20.99 Billion ≈ $14.22 Million	+1.02pp
2022-12-31	76.83%	₩29.95 Billion ≈ $20.30 Million	₩38.98 Billion ≈ $26.42 Million	-4.75pp
2021-12-31	81.59%	₩34.23 Billion ≈ $23.20 Million	₩41.96 Billion ≈ $28.43 Million	-4.13pp
2020-12-31	85.72%	₩29.81 Billion ≈ $20.20 Million	₩34.78 Billion ≈ $23.57 Million	-13.35pp
2019-12-31	99.07%	₩10.60 Billion ≈ $7.18 Million	₩10.70 Billion ≈ $7.25 Million	-0.06pp
2018-12-31	99.12%	₩10.51 Billion ≈ $7.12 Million	₩10.60 Billion ≈ $7.18 Million	-0.87pp
2017-12-31	100.00%	₩1.69 Billion ≈ $1.15 Million	₩1.69 Billion ≈ $1.15 Million	--

pp = percentage points

About Kainos Medicine Inc

KQ:284620 Korea Biotechnology

Market Cap

$24.10 Million

₩35.56 Billion KRW

Market Cap Rank

#24437 Global

#1800 in Korea

Share Price

₩1087.00

Change (1 day)

-8.81%

52-Week Range

₩977.00 - ₩1270.00

All Time High

₩28151.21